S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
Log in
NASDAQ:SRRK

Scholar Rock Stock Forecast, Price & News

$43.34
-6.61 (-13.23 %)
(As of 12/3/2020 05:09 PM ET)
Add
Compare
Today's Range
$43.13
Now: $43.34▼
$49.85
50-Day Range
$13.72
MA: $34.54▼
$49.82
52-Week Range
$7.91
Now: $43.34▼
$51.25
Volume432,450 shs
Average Volume662,363 shs
Market Capitalization$1.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.68
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, a novel inhibitor of the activation of myostatin, which is in Phase II clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Scholar Rock logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.09 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRRK
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.scholarrock.com
Phone857-259-3860
Employees93

Debt

Debt-to-Equity RatioN/A
Current Ratio4.46
Quick Ratio4.46

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.49 million
Price / Sales71.15
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.80 per share
Price / Book11.41

Profitability

EPS (Most Recent Fiscal Year)($1.85)
Net Income$-51,000,000.00
Net Margins-301.13%
Return on Equity-61.68%
Return on Assets-35.74%

Miscellaneous

Outstanding Shares33,639,000
Market Cap$1.46 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$43.34
-6.61 (-13.23 %)
(As of 12/3/2020 05:09 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SRRK News and Ratings via Email

Sign-up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions

How has Scholar Rock's stock been impacted by COVID-19 (Coronavirus)?

Scholar Rock's stock was trading at $14.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SRRK stock has increased by 191.7% and is now trading at $43.34.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Scholar Rock?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Scholar Rock or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Scholar Rock?

Wall Street analysts have given Scholar Rock a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Scholar Rock wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Scholar Rock's next earnings date?

Scholar Rock is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Scholar Rock.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) released its quarterly earnings results on Saturday, November, 14th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by $0.26. The firm earned $3.04 million during the quarter, compared to analyst estimates of $6.55 million. Scholar Rock had a negative net margin of 301.13% and a negative return on equity of 61.68%.
View Scholar Rock's earnings history.

What price target have analysts set for SRRK?

3 brokerages have issued 12-month target prices for Scholar Rock's stock. Their forecasts range from $39.00 to $52.00. On average, they anticipate Scholar Rock's share price to reach $46.00 in the next twelve months. This suggests a possible upside of 6.1% from the stock's current price.
View analysts' price targets for Scholar Rock.

Are investors shorting Scholar Rock?

Scholar Rock saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 1,240,000 shares, a drop of 62.2% from the October 31st total of 3,280,000 shares. Based on an average trading volume of 2,060,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately 5.2% of the company's stock are short sold.
View Scholar Rock's Short Interest.

Who are some of Scholar Rock's key competitors?

Some companies that are related to Scholar Rock include Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Kodiak Sciences (KOD), Halozyme Therapeutics (HALO), Fate Therapeutics (FATE), Twist Bioscience (TWST), Immunovant (IMVT), China Biologic Products (CBPO), Relay Therapeutics (RLAY), Allogene Therapeutics (ALLO), Vir Biotechnology (VIR), Ablynx (ABLYF), Beam Therapeutics (BEAM), SpringWorks Therapeutics (SWTX) and bluebird bio (BLUE).
View all competitors.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

Who are Scholar Rock's key executives?

Scholar Rock's management team includes the following people:
  • Mr. Edward H. Myles M.B.A., MBA, CFO & Head of Bus. Operations (Age 48, Pay $55k)
  • Dr. Alan J. Buckler, Chief Scientific Officer (Age 60, Pay $542.61k)
  • Dr. Yung H. Chyung M.D., Chief Medical Officer (Age 44, Pay $564.11k)
  • Mr. Stuart Anthony Kingsley M.B.A., MBA, Pres, CEO & Director (Age 56)
  • Ms. Catherine Hu, VP of Investor Relations & Corp. Communications
  • Ms. Junlin Ho J.D., Sr. VP, Head of Legal & Corp. Sec.
  • Dr. Dodzie Sogah Ph.D., Sr. VP of Corp. Devel. & Strategy
  • Ms. Lisa Amaya Price, Sr. VP of HR
  • Dr. Gregory John Carven, Head of Research
  • Ms. Erin Moore, Sr. VP of Fin. (Age 45)

When did Scholar Rock IPO?

(SRRK) raised $76 million in an IPO on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.12%), State Street Corp (1.21%), Federated Hermes Inc. (0.45%), Morgan Stanley (0.37%), Victory Capital Management Inc. (0.26%) and JPMorgan Chase & Co. (0.22%).
View institutional ownership trends for Scholar Rock.

Which major investors are selling Scholar Rock stock?

SRRK stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Acadian Asset Management LLC, State Street Corp, Squarepoint Ops LLC, JPMorgan Chase & Co., Victory Capital Management Inc., and Alps Advisors Inc..
View insider buying and selling activity for Scholar Rock.

Which major investors are buying Scholar Rock stock?

SRRK stock was purchased by a variety of institutional investors in the last quarter, including TD Asset Management Inc., UBS Asset Management Americas Inc., Federated Hermes Inc., Welch & Forbes LLC, BNP Paribas Arbitrage SA, Wells Fargo & Company MN, California Public Employees Retirement System, and Great West Life Assurance Co. Can.
View insider buying and selling activity for Scholar Rock.

How do I buy shares of Scholar Rock?

Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $43.34.

How big of a company is Scholar Rock?

Scholar Rock has a market capitalization of $1.46 billion and generates $20.49 million in revenue each year. The company earns $-51,000,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Scholar Rock employs 93 workers across the globe.

What is Scholar Rock's official website?

The official website for Scholar Rock is www.scholarrock.com.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.